Search Results
Novel non-immunological agents currently under investigation for CLL
Immunotherapies currently under investigation for CLL
Use of Novel Prognostic Markers in Practice for CLL
Exciting new agents in CLL
CLL: BTK Inhibitors in Hematologic Oncology Pathways - Pathway-Guided Choices
Abstract: Single-agent Ibrutinib 420mg Induces Durable Responses in Patients with CLL
How genomic testing is used in the prognostication and diagnosis of patients with CLL
Targeted Inhibition of Signal Molecules as Novel Therapy For CLL
New Anti-CD20 Antibodies for CLL - Are They Better than Rituximab?
First-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Pirtobrutinib vs nemtabrutinib in CLL
Reaping the Rewards of Innovative Care in CLL: From Targeted Strategies to Cellular Therapy
